212 related articles for article (PubMed ID: 30260263)
1. RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway.
Lu Y; Han D; Liu W; Huang R; Ou J; Chen X; Zhang X; Wang X; Li S; Wang L; Liu C; Miao S; Wang L; Ma C; Song W
Cancer Biol Ther; 2018; 19(12):1128-1138. PubMed ID: 30260263
[TBL] [Abstract][Full Text] [Related]
2. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of Inhibition of Apoptosis-Stimulating Protein of p53 (iASPP) Suppresses Cisplatin-Resistant Gastric Carcinoma In Vitro.
Yu J; Li L; Huang C
Med Sci Monit; 2017 Nov; 23():5542-5549. PubMed ID: 29161238
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
5. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
Zhou X; Jin W; Jia H; Yan J; Zhang G
J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
[TBL] [Abstract][Full Text] [Related]
6. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway.
Zhou J; Chen Q
FASEB J; 2019 Mar; 33(3):3420-3436. PubMed ID: 30576232
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin.
Zhang C; Zhu Q; Gu J; Chen S; Li Q; Ying L
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31072916
[TBL] [Abstract][Full Text] [Related]
8. Psoriasin overexpression confers drug resistance to cisplatin by activating ERK in gastric cancer.
Li L; Cui Y; Ye L; Zhao Z; Jiang WG; Ji J
Int J Oncol; 2018 Sep; 53(3):1171-1182. PubMed ID: 29956751
[TBL] [Abstract][Full Text] [Related]
9. Flotillin-1 promotes progression and dampens chemosensitivity to cisplatin in gastric cancer via ERK and AKT signaling pathways.
Wei J; Wang R; Lu Y; He S; Ding Y
Eur J Pharmacol; 2022 Feb; 916():174631. PubMed ID: 34774850
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
11. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp.
Lu C; Shan Z; Li C; Yang L
Biomed Pharmacother; 2017 Feb; 86():450-456. PubMed ID: 28012924
[TBL] [Abstract][Full Text] [Related]
12. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3.
Peng C; Huang K; Liu G; Li Y; Yu C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262
[TBL] [Abstract][Full Text] [Related]
13. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
Xu W; Chen Q; Wang Q; Sun Y; Wang S; Li A; Xu S; Røe OD; Wang M; Zhang R; Yang L; Zhou J
Cell Death Dis; 2014 Dec; 5(12):e1551. PubMed ID: 25476899
[TBL] [Abstract][Full Text] [Related]
14. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.
Xu W; Wang S; Chen Q; Zhang Y; Ni P; Wu X; Zhang J; Qiang F; Li A; Røe OD; Xu S; Wang M; Zhang R; Zhou J
Cell Death Dis; 2014 Feb; 5(2):e1055. PubMed ID: 24525731
[TBL] [Abstract][Full Text] [Related]
15. The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration.
Ghasabi M; Majidi J; Mansoori B; Mohammadi A; Shomali N; Shirafkan N; Baghbani E; Kazemi T; Baradaran B
J Cell Physiol; 2019 Dec; 234(12):22581-22592. PubMed ID: 31111481
[TBL] [Abstract][Full Text] [Related]
16. miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2.
Bao J; Xu Y; Wang Q; Zhang J; Li Z; Li D; Li J
Biomed Pharmacother; 2017 Aug; 92():1030-1037. PubMed ID: 28609840
[TBL] [Abstract][Full Text] [Related]
17. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
[TBL] [Abstract][Full Text] [Related]
18. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Bai M; Song N; Che X; Wang X; Qu X; Liu Y
Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513
[TBL] [Abstract][Full Text] [Related]
19. Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells.
Zhao H; Zhao D; Jin H; Li H; Yang X; Zhuang L; Liu T
Mol Med Rep; 2016 Aug; 14(2):1817-22. PubMed ID: 27357249
[TBL] [Abstract][Full Text] [Related]
20. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
